Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Parion Lands Monster Deal With Gilead For Cystic Fibrosis Candidate

This article was originally published in The Pink Sheet Daily

Executive Summary

With another CF candidate in Phase III, Gilead looks to build a respiratory disease franchise, R&D chief tells “The Pink Sheet” DAILY.

You may also be interested in...



Deal Watch: Pfizer/AstraZeneca Lead Pack Of Takeover Efforts

Pfizer’s new, increased offer for AstraZeneca on May 2 was rejected swiftly by the U.K.’s second-largest pharmaceutical company. But other companies’ acquisitive strategies have been more successful this week, with Forest announcing plans to acquire Furiex, Bristol buying out one-asset biotech iPierian, and Endo nabbing the privately owned Mexican specialty company, Somar.

Gilead Executive VP-R&D Norbert Bischofberger: An Interview With “The Pink Sheet” DAILY (Part 1 of 3)

Exec discusses the therapeutic areas Gilead’s pipeline will focus on in the future, the importance of licensing/acquisition deals and pursuing additional indications for some of the firm’s currently marketed products.

Gilead Executive VP-R&D Norbert Bischofberger: An Interview With “The Pink Sheet” DAILY (Part 1 of 3)

Exec discusses the therapeutic areas Gilead’s pipeline will focus on in the future, the importance of licensing/acquisition deals and pursuing additional indications for some of the firm’s currently marketed products.

Related Content

Topics

UsernamePublicRestriction

Register

PS066462

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel